CEO.CA Chairman's Briefing

TSXV: ACB

VANCOUVER, July 24, 2017 /CNW/ - To celebrate the graduation of Aurora Cannabis Inc. (the "Company" or "Aurora") (TSXV: ACB) (OTCQX: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) to the Toronto Stock Exchange ("TSX"), senior management, directors, key stakeholders and supporters of Aurora Cannabis will ring the opening bell today, as the company starts trading on Toronto Stock Exchange

Now trading on Canada's flagship stock exchange, Aurora previously began trading on the TSX Venture exchange in October of 2016. Since that time, the Company has achieved significant commercial and operational progress including:

• Approximately doubling its active registered patients
• Approximately tripling monthly revenue, with increased revenue per patient
• Adding $600M in shareholder value, from ~ $350M to ~ $950M
• Raising $175M in financing
• Making rapid progress on construction of Aurora Sky, which is anticipated to be the world's largest capacity, most advanced cannabis production facility
• Acquiring a third production facility in Pointe-Claire, Québec
• Launching international expansion in Australia and Germany
• Raising the bar on product quality and safety for whole industry, with the world's most comprehensive and transparent cannabis testing and disclosure protocol
• Establishing Aurora as the second largest cannabis company in the world by market capitalization

About Aurora

Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, and is currently constructing a second 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton International Airport, and has acquired, and is undertaking completion of, a third 40,000 square foot production facility in Pointe-Claire, Quebec, on Montreal's West Island. In addition, the company is the cornerstone investor with a 19.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis, as well as owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union ("EU"), based in Germany. Aurora's common shares trade on the TSX-V under the symbol "ACB".

On behalf of the Board of Directors, 
AURORA CANNABIS INC.
Terry Booth, CEO

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

Neither TSX nor TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of TSX and TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Aurora Cannabis Inc.

View original content: http://www.newswire.ca/en/releases/archive/July2017/24/c3451.html